Category: News

Australian independent video game producer PlaySide Studios is preparing its next title for PC after signing a deal with Click Management and two leading video game influencers.

Bitcoin prices have hit an all-time high after Elon Musk’s Tesla bought $1.5 billion worth of the cryptocurrency last week. Following the announcement, bitcoin immediately surged 13% and has continued to grow in value.

Australian smart locker provider TZ Limited (ASX: TZL) is continuing to expand its University client base across North America after installing its technology at Fairfield University, Connecticut.

Gold is holding firmly to its 2020 gains in the new year, as forecasts from leading global financial institutions point to fresh highs for the precious metal in the coming twelve months.

Australian listed biotech company Prescient Therapeutics (ASX: PTX) is forging a path for other prospective cancer treatments, by developing a platform to improve the performance of CAR T drugs.

Australian gold and copper explorer TechGen Metals is turning its attention to two gold projects near Kalgoorlie as it readies itself for an IPO later this year.

Zenith Minerals (ASX:ZNC) is a gold exploration company that identifies, explores and develops base and precious metals around Australia.

Pivotal Systems (ASX: PVS) designs and sells industry leading flow control subsystems for semiconductor processing equipment, that give a significant competitive advantage to the largest semiconductor producers in the world.

Australian uranium explorer Marenica Energy (ASX: MEY) is priming itself for an expected increase in uranium prices as the supply deficit worsens.

American universities have tapped Australian smart locker company, TZ SMArt Lockers (ASX:TZL), to provide storage solutions to reduce the number of students waiting in tightly-packed queues to collect packages.

From dental hygiene to FIFO flight operators, Yarra Capital Management microcaps portfolio manager Joel Fleming says investors can find opportunities for fast growth in the small end of town.

Several major pharmaceutical companies have cautioned they’re unable to widely use revolutionary CAR-T cancer treatments, until an “off-the-shelf product” becomes available – highlighting the need to address current technology bottlenecks to drive down costs, and bring CAR-T therapy to more patients.